Lyrfigtu (lirafugratinib hydrochloride)

Where it stands

Lyrfigtu (lirafugratinib hydrochloride), from Elevar, is approved in the US. The records show an FDA approval dated 2026-09-23 under NDA220425, and the product is supplied as a capsule. The FDA describes it as a new medicine.

The records leave several fields empty: the therapeutic area and the approved indication. This analysis therefore cannot say which patients or conditions the product is approved for, or what limits apply to its use. The label would be the authoritative source for this.

The CHMP opinion date is blank. That fits a US-only record, because CHMP is the EU committee and the records show no EU procedure for this product.

Regulatory pathway and designations

The records list two designations: New molecular entity and Priority review. An NME is an active ingredient that has not previously been approved by the FDA, either alone or in combination. The application was filed as a New Drug Application (NDA220425).

Priority review is an FDA designation for applications that, if approved, would offer a significant improvement in the safety or effectiveness of treating, diagnosing or preventing a serious condition. As a matter of general procedure, it shortens the FDA's target review timeline compared with standard review. The records do not give the submission date, filing date or PDUFA goal date, so the actual review duration cannot be assessed.

The records do not show whether other expedited programs applied, such as Breakthrough Therapy, Fast Track or Accelerated Approval. They also do not show whether the approval carries postmarketing requirements or commitments, and no such status should be assumed.

Safety and pharmacovigilance

The records contain no safety information for Lyrfigtu, including warnings, contraindications, adverse reaction data, a risk management program or postmarketing study requirements, so no safety assessment can be made here.

As general context only, a newly approved NME enters routine US postmarketing surveillance, including adverse event reporting to the FDA. Product-specific safety conclusions need the approved prescribing information.

What to watch

The first priority is to obtain the approved US prescribing information and the FDA approval documents. They would show the indication, dosing, safety language, and any postmarketing requirements or commitments, none of which are in the records.

Professionals should also check for a US launch announcement and for any filings elsewhere. The records show no EU or other regional procedure, so any ex-US plans from Elevar would need to be confirmed from other sources.

Business-development and medical teams should note that the therapeutic area and indication fields are blank in the source data. Any competitive or clinical positioning should wait until those are verified against the label.